title: Hypoxia--a key regulatory factor in tumour growth.
abstract: Cells undergo a variety of biological responses when placed in hypoxic conditions, including activation of signalling pathways that regulate proliferation, angiogenesis and death. Cancer cells have adapted these pathways, allowing tumours to survive and even grow under hypoxic conditions, and tumour hypoxia is associated with poor prognosis and resistance to radiation therapy. Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting.
authors.affiliation: Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK. L.Richards@icrf.icnet.uk
authors.forename: Adrian L
authors.initials: AL
authors.lastname: Harris
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics; D017209:Apoptosis; D051784:Aryl Hydrocarbon Receptor Nuclear Translocator; D051792:Basic Helix-Loop-Helix Proteins; D002455:Cell Division; D015687:Cell Hypoxia; D002470:Cell Survival; D017362:Cyclic AMP Response Element-Binding Protein / Q000502:physiology; D004249:DNA Damage; D004268:DNA-Binding Proteins / Q000502:physiology*; D019281:Dimerization; D005314:Embryonic and Fetal Development; D016228:Endothelial Growth Factors / Q000502:physiology; D004921:Erythropoietin / Q000627:therapeutic use; D005544:Forecasting; D005786:Gene Expression Regulation; D006019:Glycolysis; D006801:Humans; D006863:Hydrogen-Ion Concentration; D051793:Hypoxia-Inducible Factor 1; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D008222:Lymphokines / Q000502:physiology; D051379:Mice; D016328:NF-kappa B / Q000502:physiology; D009369:Neoplasms / Q000098:blood supply / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000378:metabolism; D009687:Nuclear Proteins / Q000502:physiology*; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D010100:Oxygen / Q000378:metabolism; D011355:Prodrugs / Q000493:pharmacokinetics; D011518:Proto-Oncogene Proteins / Q000502:physiology; D020794:Receptor Protein-Tyrosine Kinases / Q000502:physiology; D018336:Receptors, Aryl Hydrocarbon; D015398:Signal Transduction; D015534:Trans-Activators / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D014157:Transcription Factors / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A; D040281:Vascular Endothelial Growth Factor Receptor-1; D042442:Vascular Endothelial Growth Factors; D023041:Xenograft Model Antitumor Assays; D000099162:Endothelial PAS Domain-Containing Protein 1
chemical_list: D000970:Antineoplastic Agents; D051784:Aryl Hydrocarbon Receptor Nuclear Translocator; D051792:Basic Helix-Loop-Helix Proteins; D017362:Cyclic AMP Response Element-Binding Protein; D004268:DNA-Binding Proteins; D016228:Endothelial Growth Factors; D004921:Erythropoietin; D051793:Hypoxia-Inducible Factor 1; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D008222:Lymphokines; D016328:NF-kappa B; D009687:Nuclear Proteins; D010100:Oxygen; D011355:Prodrugs; D011518:Proto-Oncogene Proteins; D020794:Receptor Protein-Tyrosine Kinases; D018336:Receptors, Aryl Hydrocarbon; D015534:Trans-Activators; D014157:Transcription Factors; D042461:Vascular Endothelial Growth Factor A; D040281:Vascular Endothelial Growth Factor Receptor-1; D042442:Vascular Endothelial Growth Factors; D000099162:Endothelial PAS Domain-Containing Protein 1; C497396:ARNT protein, human; C497397:Arnt protein, mouse; C497442:HIF1A protein, human; C497443:Hif1a protein, mouse